X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs AUROBINDO PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD AUROBINDO PHARMA ALEMBIC LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 53.4 19.5 273.3% View Chart
P/BV x 2.2 3.9 56.3% View Chart
Dividend Yield % 0.5 0.3 144.6%  

Financials

 ALEMBIC LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
AUROBINDO PHARMA
Mar-18
ALEMBIC LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs72809 8.9%   
Low Rs34504 6.7%   
Sales per share (Unadj.) Rs4.7281.1 1.7%  
Earnings per share (Unadj.) Rs6.141.4 14.8%  
Cash flow per share (Unadj.) Rs6.250.9 12.3%  
Dividends per share (Unadj.) Rs0.202.50 8.0%  
Dividend yield (eoy) %0.40.4 99.2%  
Book value per share (Unadj.) Rs40.7199.4 20.4%  
Shares outstanding (eoy) m267.03585.88 45.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.3 482.3%   
Avg P/E ratio x8.715.9 54.6%  
P/CF ratio (eoy) x8.512.9 65.7%  
Price / Book Value ratio x1.33.3 39.5%  
Dividend payout %3.36.0 54.2%   
Avg Mkt Cap Rs m14,139384,630 3.7%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m20721,308 1.0%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m1,255164,666 0.8%  
Other income Rs m3701,020 36.3%   
Total revenues Rs m1,625165,686 1.0%   
Gross profit Rs m11137,718 0.3%  
Depreciation Rs m385,580 0.7%   
Interest Rs m2777 0.2%   
Profit before tax Rs m44232,380 1.4%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m248,183 0.3%   
Profit after tax Rs m1,63024,229 6.7%  
Gross profit margin %8.922.9 38.6%  
Effective tax rate %5.425.3 21.5%   
Net profit margin %129.814.7 882.5%  
BALANCE SHEET DATA
Current assets Rs m1,867121,878 1.5%   
Current liabilities Rs m59186,806 0.7%   
Net working cap to sales %101.621.3 477.2%  
Current ratio x3.21.4 224.9%  
Inventory Days Days94130 72.6%  
Debtors Days Days7468 107.6%  
Net fixed assets Rs m1,79181,037 2.2%   
Share capital Rs m534586 91.2%   
"Free" reserves Rs m10,324116,218 8.9%   
Net worth Rs m10,858116,804 9.3%   
Long term debt Rs m414,512 0.9%   
Total assets Rs m11,591211,052 5.5%  
Interest coverage x260.942.7 611.5%   
Debt to equity ratio x00 9.8%  
Sales to assets ratio x0.10.8 13.9%   
Return on assets %14.111.8 118.8%  
Return on equity %15.020.7 72.4%  
Return on capital %15.227.4 55.5%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1980,727 0.0%   
Fx outflow Rs m26434,700 0.8%   
Net fx Rs m-24446,027 -0.5%   
CASH FLOW
From Operations Rs m23619,548 1.2%  
From Investments Rs m-224-19,570 1.1%  
From Financial Activity Rs m-278,642 -0.3%  
Net Cashflow Rs m-158,922 -0.2%  

Share Holding

Indian Promoters % 64.0 54.1 118.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.5%  
FIIs % 9.7 27.7 35.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.2 255.9%  
Shareholders   54,701 69,601 78.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON   

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Mar 22, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS